Abstract

QRISK performed at least as well as the Framingham model for discrimination and was better calibrated to the UK population than either the Framingham model or ASSIGN. QRISK is likely to provide more appropriate risk estimates to help identify high risk patients on the basis of age, sex, and social deprivation. It is therefore likely to be a more equitable tool to inform management decisions and help ensure treatments are directed towards those most likely to benefit. It includes additional variables which improve risk estimates for patients with a positive family history or those on antihypertensive treatment. However, since the validation was performed in a similar population to the population from which the algorithm was derived, it potentially has a "home advantage." Further validation in other populations is therefore required.

Keywords

MedicineFramingham Risk ScoreCohortProspective cohort studyInternal medicineCohort studyMyocardial infarctionBody mass indexBlood pressureUnited Kingdom Prospective Diabetes StudyDiseaseDiabetes mellitusType 2 diabetesEndocrinology

Affiliated Institutions

Related Publications

Publication Info

Year
2007
Type
article
Volume
335
Issue
7611
Pages
136-136
Citations
993
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

993
OpenAlex

Cite This

Julia Hippisley‐Cox, Carol Coupland, Yana Vinogradova et al. (2007). Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ , 335 (7611) , 136-136. https://doi.org/10.1136/bmj.39261.471806.55

Identifiers

DOI
10.1136/bmj.39261.471806.55